X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to fund Moderna’s influenza program, including mRNA-1010, a quadrivalent seasonal influenza vaccine encoding hemagglutinin (HA) glycoproteins of four flu strains administered intramuscularly.
Lead Product(s): mRNA-1010
Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1010
Highest Development Status: Phase IIIProduct Type: Vaccine
Recipient: Moderna Therapeutics
Deal Size: $750.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 27, 2024
Details:
The proceeds will be used to fund the ongoing operations of the company, including Galafold (migalastat), a small molecule and the first and only oral therapy for adults with Fabry disease and an amenable GLA variant.
Lead Product(s): Migalastat
Therapeutic Area: Genetic Disease Product Name: Galafold
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Amicus Therapeutics
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 02, 2023
Details:
The financing will be used for the continued pipeline advancement and further development of its cell-free protein synthesis and site-specific conjugation technologies, including VAX-24, a Phase 3 ready, 24-valent next-generation pneumococcal conjugate vaccine.
Lead Product(s): 24-valent Pneumococcal Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: VAX-24
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: Sutro Biopharma
Deal Size: $390.0 million Upfront Cash: $140.0 million
Deal Type: Collaboration June 26, 2023
Details:
The strategic financing will support the acceleration of PTC’s robust and diversified pipeline having lead asset Translarna (ataluren), business development opportunities and general corporate purposes.
Lead Product(s): Ataluren
Therapeutic Area: Genetic Disease Product Name: Translarna
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: PTC Therapeutics
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration October 27, 2022
Details:
The restructured agreement allows for a return on capital already invested by Blackstone, and also provides Blackstone with option to make a passive financial investment in nadofaragene firadonavec (rAd-IFN/Syn3) upon achievement of a specified regulatory event.
Lead Product(s): Nadofaragene Firadonavec
Therapeutic Area: Oncology Product Name: rAd-IFN/Syn3
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Recipient: Ferring Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 17, 2022
Details:
For the Sarclisa® subcutaneous formulation delivery, Sanofi has partnered with drug delivery technology innovator company to advance the development of a subcutaneous delivery for Sarclisa® with the goal of offering a unique patient-centric treatment experience.
Lead Product(s): Isatuximab,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Sarclisa
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Sanofi
Deal Size: $330.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 15, 2022
Details:
Obecabtagene Autoleucel (Obe-cel) is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies used in adult ALL and B-NHL.
Lead Product(s): Obecabtagene Autoleucel
Therapeutic Area: Oncology Product Name: Obe-cel
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Autolus Therapeutics
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition November 08, 2021
Details:
The portfolio to be divested includes a variety of over-the-counter medicines and health products. TCHC’s strong regional brands include Alinamin, and Benza.
Lead Product(s): Fursultiamine
Therapeutic Area: Ophthalmology Product Name: Alinamin
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Takeda Pharmaceutical
Deal Size: $2,300.0 million Upfront Cash: Undisclosed
Deal Type: Divestment August 24, 2020
Details:
The investment includes up to $70 million to support the ongoing HELIOS-B Phase 3 study of vutrisiran in ATTR amyloidosis patients with cardiomyopathy, and up to $80 million to support Phase 2 & Phase 3 development of ALN-AGT, in development for the treatment of hypertension.
Lead Product(s): Vutrisiran
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Alnylam Pharmaceuticals
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 17, 2020
Details:
Funding will support Medtronic's Diabetes R&D, including a series of near-term programs such as the MiniMed™ 780G insulin pump system, its Personalized Closed Loop (PCL) system, extended wear infusion set, and Zeus and Synergy sensors.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: MiniMed 780G
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Medtronic Plc
Deal Size: $337.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
